Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.

Trial Profile

Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
  • Indications Congenital heart defects
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ELPIS
  • Most Recent Events

    • 27 Feb 2018 According to Longeveron media release, trial has officially started with the first patient receiving the company's mesenchymal stem cell therapy in a procedure performed at the University of Maryland Medical Center in Baltimore.
    • 26 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top